AtaiBeckley (ATAI) Assets Average (2021 - 2026)

AtaiBeckley's (ATAI) quarterly Assets Average came in at $278.8 million in Q1 2026.

AtaiBeckley (ATAI) Assets Average (2021 - 2026) Analysis & Trends

AtaiBeckley's Assets Average history runs 1 years deep, the most recent figure standing at $278.8 million for Q1 2026.

For the quarter ending Q1 2025, Assets Average fell 71.08% year-over-year to $81.3 million; the trailing twelve-month figure through Mar 2025 stood at $81.3 million (down 71.08% YoY), and the FY2024 full-year result was $226.4 million, down 24.39% from the prior year.
Assets Average fell to $81.3 million in Q1 2025, from $242.4 million in the prior quarter.
In the past five years, Assets Average ranged from a high of $324.0 million in Q4 2022 to a low of $885000.0 in Q2 2021.
A 5-year average of $173.5 million and a median of $254.8 million in 2023 frame the typical range for Assets Average.
Across the five-year window, Assets Average soared 11377.83% in 2022 and plunged 71.08% in 2025, its largest moves.
Tracing ATAI's Assets Average over 5 years: stood at $2.8 million in 2021, then soared by 11377.83% to $324.0 million in 2022, then dropped by 7.15% to $300.8 million in 2023, then dropped by 19.41% to $242.4 million in 2024, then slumped by 66.45% to $81.3 million in 2025.
Business Quant data shows ATAI's Assets Average at $81.3 million in Q1 2025, $242.4 million in Q2 2024, and $281.3 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	303.40 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	65.01 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	8.37 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	41.64 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	26.06 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	40.71 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	795.91 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	2.30 Bn
10	AtaiBeckley	2.56 Bn	2.56 Bn	-	-

Download Data